SCHEMBL22897264

SCHEMBL22897264

Cc1nnn(-c2ccccc2)c1C(=O)O

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.60
TP53 P04637 3/20 0.48
ALOX12 P18054 1/20 0.48
CYP1A2 P05177 1/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47
KDM4E B2RXH2 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
ALDH1A1 P00352 2/20 0.47
SLC5A1 P13866 1/20 0.45
SLC5A2 P31639 1/20 0.45
POLB P06746 2/20 0.44
MAPK1 P28482 2/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
PTGS2 P35354 1/20 0.43
APEX1 P27695 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
GPBAR1 Q8TDU6 1/20 0.42
NPC1 O15118 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30684467 0.86 HTT (0.53) HTTTP53ALOX12CYP1A2CYP2C9
SCHEMBL20028108 0.85 GAA (0.51) HTTTP53CYP1A2CYP2C9CYP2C19
SCHEMBL14710217 0.85 SLC5A1 (0.46) HTTKDM4EALDH1A1SLC5A1SLC5A2
SCHEMBL13754468 0.85 PTGS2 (0.55) HTTTP53SLC5A1SLC5A2MEN1
SCHEMBL16697717 0.83 RPA1 (0.44) HTTTP53KDM4ESMN1; SMN2ALDH1A1
SCHEMBL15897901 0.82 SMN1; SMN2 (0.50) HTTTP53KDM4ESMN1; SMN2ALDH1A1
SCHEMBL31297182 0.81 HTT (0.41) HTTTP53ALOX12KDM4ESLC5A1
SCHEMBL20028111 0.81 TP53 (0.66) HTTTP53ALOX12CYP2C9CYP2C19
SCHEMBL12543895 0.79 PDE4B (0.45) HTTTP53KDM4ESMN1; SMN2ALDH1A1
SCHEMBL30111767 0.79 HTT (0.39) HTTKDM4ESMN1; SMN2ALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240425491-A1 HETEROARYL COMPOUNDS USEFUL IN THE TREATMENT OF COGNITIVE DISORDERS DRAIG THERAPEUTICS LTD (GB) 2024-12-26 US disclosed
EP-4334301-A1 HETEROARYL COMPOUNDS USEFUL IN THE TREATMENT OF COGNITIVE DISORDERS University College Cardiff Consultants Limited (GB) 2024-03-13 EP disclosed
CN-117279908-A Heteroaryl compounds for the treatment of cognitive disorders 加的夫大学学院咨询有限公司 2023-12-22 CN disclosed
WO-2022234271-A1 HETEROARYL COMPOUNDS USEFUL IN THE TREATMENT OF COGNITIVE DISORDERS UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) 2022-11-10 WO disclosed
US-11339130-B1 Calpain modulators and therapeutic uses thereof BLADE THERAPEUTICS, INC. (US) 2022-05-24 US disclosed
US-10934261-B2 Calpain modulators and therapeutic uses thereof BLADE THERAPEUTICS, INC. (US) 2021-03-02 US disclosed
US-10894776-B2 2021-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10934261-B2 Calpain modulators and therapeutic uses thereof CAPNS1, CAPN9, CAPN1 HTT 889/4885TP53 1804/4885ALOX12 3375/4885
US-10894776-B2 CAPNS1, CAPN9, CAPN2 HTT 740/4885TP53 1368/4885ALOX12 3119/4885
US-11339130-B1 Calpain modulators and therapeutic uses thereof CAPNS1, CAPN9, CAPN1 HTT 889/4885TP53 1804/4885ALOX12 3375/4885
US-20240425491-A1 HETEROARYL COMPOUNDS USEFUL IN THE TREATMENT OF COGNITIVE DISORDERS GABRA5, GABRB3, GABRA3 HTT 2469/4885TP53 4323/4885ALOX12 3744/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.